Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial

OBJECTIVE: As the cost-effectiveness evaluation of cinacalcet and conventional therapy in China has not been reported, the objective of this study was to make a pharmacoeconomic evaluation of cinacalcet specific to the Chinese healthcare setting in patients with moderate-to-severe secondary hyperpar...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lin, Hong, Dongsheng, Ma, Kuifen, Wu, Bin, Lu, Xiaoyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406115/
https://www.ncbi.nlm.nih.gov/pubmed/32753447
http://dx.doi.org/10.1136/bmjopen-2019-034123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406115/
https://www.ncbi.nlm.nih.gov/pubmed/32753447
http://dx.doi.org/10.1136/bmjopen-2019-034123

Ejemplares similares